- Home
- TBN vs CDXS Comparison
TBN vs CDXS Comparison
Compare TBN & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBN
- CDXS
- Stock Information
- Founded
- TBN 2009
- CDXS 2002
- Country
- TBN Australia
- CDXS United States
- Employees
- TBN N/A
- CDXS N/A
- Industry
- TBN
- CDXS Major Chemicals
- Sector
- TBN
- CDXS Industrials
- Exchange
- TBN NYSE
- CDXS Nasdaq
- Market Cap
- TBN 362.7M
- CDXS 361.3M
- IPO Year
- TBN 2024
- CDXS 2010
- Fundamental
- Price
- TBN $26.98
- CDXS $4.18
- Analyst Decision
- TBN Buy
- CDXS Buy
- Analyst Count
- TBN 3
- CDXS 2
- Target Price
- TBN $34.67
- CDXS $11.00
- AVG Volume (30 Days)
- TBN 45.6K
- CDXS 566.1K
- Earning Date
- TBN 02-12-2025
- CDXS 02-27-2025
- Dividend Yield
- TBN N/A
- CDXS N/A
- EPS Growth
- TBN N/A
- CDXS N/A
- EPS
- TBN N/A
- CDXS N/A
- Revenue
- TBN N/A
- CDXS $64,446,000.00
- Revenue This Year
- TBN N/A
- CDXS N/A
- Revenue Next Year
- TBN N/A
- CDXS $2.02
- P/E Ratio
- TBN N/A
- CDXS N/A
- Revenue Growth
- TBN N/A
- CDXS N/A
- 52 Week Low
- TBN $15.75
- CDXS $2.56
- 52 Week High
- TBN $34.50
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- TBN N/A
- CDXS 41.30
- Support Level
- TBN N/A
- CDXS $4.14
- Resistance Level
- TBN N/A
- CDXS $4.41
- Average True Range (ATR)
- TBN 0.00
- CDXS 0.22
- MACD
- TBN 0.00
- CDXS 0.01
- Stochastic Oscillator
- TBN 0.00
- CDXS 38.89
About TBN TAMBORAN RESOURCES CORPORATION
Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.